- Home
- PEBO vs GKOS Comparison
PEBO vs GKOS Comparison
Compare PEBO & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEBO
- GKOS
- Stock Information
- Founded
- PEBO 1902
- GKOS 1998
- Country
- PEBO United States
- GKOS United States
- Employees
- PEBO N/A
- GKOS 995
- Industry
- PEBO Major Banks
- GKOS Medical/Dental Instruments
- Sector
- PEBO Finance
- GKOS Health Care
- Exchange
- PEBO Nasdaq
- GKOS Nasdaq
- Market Cap
- PEBO N/A
- GKOS 5.1B
- IPO Year
- PEBO N/A
- GKOS 2015
- Fundamental
- Price
- PEBO $27.85
- GKOS $90.26
- Analyst Decision
- PEBO Buy
- GKOS Strong Buy
- Analyst Count
- PEBO 5
- GKOS 13
- Target Price
- PEBO $37.90
- GKOS $155.00
- AVG Volume (30 Days)
- PEBO 170.1K
- GKOS 1.0M
- Earning Date
- PEBO 04-22-2025
- GKOS 04-30-2025
- Dividend Yield
- PEBO 5.76%
- GKOS N/A
- EPS Growth
- PEBO N/A
- GKOS N/A
- EPS
- PEBO 3.31
- GKOS N/A
- Revenue
- PEBO $565,394,000.00
- GKOS $383,481,000.00
- Revenue This Year
- PEBO N/A
- GKOS $27.84
- Revenue Next Year
- PEBO $4.37
- GKOS $27.99
- P/E Ratio
- PEBO $8.41
- GKOS N/A
- Revenue Growth
- PEBO 17.02
- GKOS 21.85
- 52 Week Low
- PEBO $26.21
- GKOS $77.91
- 52 Week High
- PEBO $37.07
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- PEBO 41.47
- GKOS 41.57
- Support Level
- PEBO $26.40
- GKOS $86.16
- Resistance Level
- PEBO $28.97
- GKOS $94.55
- Average True Range (ATR)
- PEBO 1.08
- GKOS 6.54
- MACD
- PEBO 0.03
- GKOS 1.11
- Stochastic Oscillator
- PEBO 44.93
- GKOS 54.51
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.